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abstract
PURPOSE Given the increasing burden of cancer on patients, health care providers, and payers, the shift of
certain outpatient procedures to the patients’ homes (further indicated as oncologic home-hospitalization
[OHH]) might be a high-quality, patient-centered, and cost-effective alternative to standard ambulatory cancer
care (SOC).
METHODSA randomized-controlled trial was conducted to evaluate the quality of a locally implementedmodel for
OHH (n = 74) compared with SOC (n = 74). The model for OHH consisted of home administration of certain
subcutaneous cancer drugs (full OHH) and home nursing assessments before ambulatory systemic cancer
therapy (partial OHH). Quality was evaluated based on patient-reported quality of life (QoL) and related end
points; service use and cost data; safety data; patient-reported satisfaction and preferences; and model effi-
ciency. An equivalence design was used for primary end point analysis. Participants were followed during
12 weeks of systemic cancer treatment.
RESULTS This trial demonstrated equivalence of both models (OHH v SOC) in terms of patient-reported QoL (95%
CI not exceeding the equivalence margin of 10%). Full OHH resulted in significantly less hospital visits (mean of
5.66 3.0 v 13.26 4.6;P= .011). Partial OHH reducedwaiting times for therapy administration at the day care unit
with 45% per visit (2 hours 36 minutes 6 1 hour 4 minutes v 4 hours 6 1 hour 4 minutes; P , .001). No safety
issues were detected. Of the intervention group, 88% reported to be highly satisfied with the OHHmodel, and 77%
reported a positive impact on their QoL. At study end, 60% of both study arms preferred OHH above SOC.
CONCLUSION The shift of particular procedures from the outpatient clinic to the patients’ homes offers a high-
quality and patient-centered alternative for a large proportion of patients with cancer. Further research is needed
to evaluate potential cost-efficiency.
JCO Global Oncol 7:1564-1571. © 2021 by American Society of Clinical Oncology
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INTRODUCTION
Today, the globally increasing cancer burden has a
significant impact on public health. Health care fa-
cilities must meet the growing specialized care de-
mand, whereas governments are forced to deal with
increasing costs.1,2
The exploration and implementation of value-based
health care models, offering high-quality personalized
care at the most efficient cost, is encouraged.3,4
According to the Institute of Medicine, health care
models should rely on six domains of quality, which are
safety, effectiveness, patient-centeredness, timeli-
ness, efficiency, and equitably.5 A potential patient-
centered and cost-effective care model for patients
with cancer undergoing systemic treatment is home-
hospitalization, defined as a service that provides
active treatment by health care professionals in the
patient’s home, for a condition that otherwise would
require acute hospital inpatient care.6 The possibilities
for home-hospitalization within the domain of oncology
have been evaluated in different countries and dif-
ferent settings. In general, these initiatives were con-
sidered feasible, patient-centered, and safe. However,
robust scientific evidence on the overall quality and
cost-effectiveness is scarce.7-9
This randomized-controlled clinical trial is part of a
larger project investigating the feasibility of imple-
menting a model for oncologic home-hospitalization
(OHH) in the Belgian health care system. The objective
of this randomized-controlled clinical trial was to es-
tablish the quality of a locally implemented model for
OHH in comparison with the standard ambulatory
cancer care (SOC). Quality was evaluated based on (1)
patient-reported outcome measures (PROMs) for
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use and cost data, (3) safety data, (4) patient-reported
satisfaction and preferences, and (5) model efficiency.
METHODS
This randomized-controlled trial was conducted in the
cancer center of the AZ Groeninge general hospital, Kor-
trijk, Belgium. The study protocol was approved by the local
ethics committee (registration number: B396201733129)
and was carried out in compliance with good clinical
practice guidelines. Written informed consent was obtained
from all participants. This trial was registered on the
ClinicalTrials.gov database (identifier: NCT03668275).
Patients
Patients eligible for this study had to be age 18 years or
older, had a good performance status (Eastern Cooperative
Oncology Group ≤ 2), lived within a 30 minutes’ drive from
the hospital, and were diagnosed with a solid tumor or
hematologic malignancy for which they were (re)starting
active treatment of curative, palliative (ie, noncurative
treatments), or supportive nature (ie, blood transfusions) at
the oncology day care unit (DCU). Patients with prob-
lematic venous access, known problems with therapy
administration, simultaneous radiotherapy treatment,
, 12 weeks of planned therapy, language barriers, or
communication difficulties were excluded for participation.
Participants were randomly assigned to OHH or SOC based
on the principle of minimization. Stratification was based on
(1) type of treatment (subcutaneous therapy eligible for full
home-administration, other therapies not eligible for full
home-administration or transfusion), (2) prior systemic
cancer drug treatment (yes or no), and (3) age (, 65
or ≥ 65 years).
Study Interventions
OHH, as organized in this study, was implemented to
optimize ambulatory care for patients receiving systemic
cancer treatment at the oncology DCU. According to the
SOC, each hospital visit for administration of cancer therapy
starts with a blood collection and intravenous line access
provision, after which a nursing review, toxicity scoring,
and monitoring of vital signs take place. These are con-
sidered the preparatory assessments allowing the oncolo-
gist or hematologist to prescribe patient-specific cancer
treatment.
The introducedmodel for OHHwas dual. For most patients,
the home-intervention comprised all preparatory assess-
ments required before administration of the cancer therapy
itself. This included nursing review, toxicity scoring,
monitoring of vital signs, blood sampling, and intravenous
line access provision. These assessments were performed
1 day before actual therapy administration at the oncology
DCU (day –1), enabling the oncologist to prescribe and the
pharmacy to prepare cancer therapy before arrival of the
patient at the hospital. This part of our home-hospitalization
model is further indicated as partial OHH. For those pa-
tients receiving subcutaneous injections of bortezomib or
azacitidine, all injections were administered at the patients’
homes, with the exception of the first administration of each
consecutive treatment cycle. This part is further indicated
as full OHH as these home visits fully replaced the need of a
hospital visit. Home visits were conducted by certified
oncology nurses employed by the hospital and in accor-
dance with the standard procedures.
Outcome Measures
Patient-reported health-related QoL was measured using
the functional assessment of cancer therapy questionnaire
(FACT-G, v4).10 General QoL and related end points were
measured using the EuroQol questionnaire (EQ-5D-3L;
consisting of a visual analog scale [VAS] and generic
questionnaire [GQ])11; the distress barometer (consisting of
a distress thermometer [DT] and colored complaint scale
CONTEXT
Key Objective
The shift of certain outpatient procedures to the patients’ homes (further indicated as oncologic home-hospitalization [OHH])
might deal with the increasing burden of cancer on patients in need of systemic treatment and ambulatory health care
facilities.
Knowledge Generated
A randomized-controlled equivalence trial evaluating the quality of a locally implemented model for OHH compared with
standard ambularory cancer care is described. The model for OHH consisted of home administration of certain sub-
cutaneous cancer drugs and home nursing assessments before ambulatory systemic cancer therapy. Quality was
evaluated based on patient-reported outcomemeasures for quality of life and related end points; service use and cost data;
safety data; patient-reported satisfaction and preferences; and model efficiency.
Relevance
The results of this trial demonstrated that a shift of particular procedures from the outpatient clinic to the patients’ homes offers
a high-quality and patient-centered alternative for a large proportion of patients with cancer. Further research is needed to
evaluate potential cost-efficiency.
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[CCS]),12 and the hospital anxiety and depression scale
(HADS).13 The choice of this set of PROMs was based on
the measurement properties established in the setting of
interest during a preceding pilot study.14 Patients were
asked to complete their service use and cost data during
the first 12 weeks of cancer therapy in a study-specific
costs form. Additional and/or missing data on service use
(defined as the number of home and DCU visits, as well as
the number of hospitalization days) were collected from the
patients’ electronic health record. Adverse events related to
the home-intervention were recorded by the treating
nurses, and patients were asked to complete a question-
naire based on the patient-reported experiences and out-
comes of safety in primary care questionnaire (PREOS-
PC).15 In addition, patients were questioned about their
feeling of safety at regular time points using a VAS. The
homecare nurses had to register safety issues in the
hospital’s incident reporting system if they felt safety was
compromised during their work. Patient satisfaction was
measured using the cancer outpatients’ satisfaction with
care questionnaires (OUT-PATSAT35).16,17 In addition, a
study-specific questionnaire—designed based on the re-
sults of a pilot study14—was used to question patients’
satisfaction and preferences for the explored care model.
Besides, this additional questionnaire was used to ask
patients directly whether they experienced an effect of the
intervention on their QoL. As a measure for model effi-
ciency, the waiting times for therapy administration at the
DCU were registered for both groups, as well as the number
of avoided hospital visits in case laboratory values on day –1
predicted the need of postponing therapy. Waiting times
were calculated as the difference between the time of
patient arrival at the DCU and the administration of the
anticancer product, which were both collected from the
electronic health record.
PROMs were presented to both patient groups at the start of
their oncologic treatment and subsequently every 4 weeks
up to 3 months later. After 12 weeks of study participation,
patients from the control group could opt to cross-over. A final
follow-up was planned 20 weeks after the start of the study.
Statistical Analysis
On the basis of a two-sided equivalence sample size cal-
culation, given a noninferiority or superiority margin of 10%
on FACT-G and mean, deviation, and dropout rate as
calculated in the pilot study,14 a sample size of 130 patients
was considered appropriate to provide 80% power to es-
tablish the assumption of equivalence.
Baseline characteristics were compared using exact two-
sided chi-square tests and two-sample t-tests. Missing data
in the primary outcome variable were assessed using a
missing data pattern matrix and assumed to be at random.
Predictor variables were identified using the MICE package
software in R. Linear mixed-effect models were used to
evaluate the PROM results over time and between both
study groups (the time × group interaction effect). The
model was additionally corrected for the predictors of
missingness and strata variables. The unstructured co-
variance structure was selected for the residuals over time.
Estimated marginal means for each time point for both
groups were calculated, and a post hoc pairwise com-
parison of the time × group effect was conducted. The
same statistical model was used to evaluate the potential
time × group effect on the secondary end point PROMs:
EQ-5D-3L (GQ and VAS), DT, CCS, and HADS.
The data on service use and model efficiency were eval-
uated using two-sample t-tests. Data from those patients
who stopped study participation because of the home-
intervention (n = 4) were excluded from these analyses.
P values below .05 were considered statistically significant.




Between May 2018 and January 2019, all patients (re)
starting systemic cancer treatment at the oncology DCU
were screened for participation. In total, 103 patients of the
251 meeting the inclusion criteria declined participation
(41%). Of those patients eligible for subcutaneous therapy
at home, only one out of 12 patients declined. Finally, 148
patients were randomly assigned to OHH (n = 74) or SOC
(n = 74; Fig 1). Four patients of the OHH group dis-
continued study participation prematurely. Two of them felt
the intravenous line placed felt uncomfortable at night and
two others decided the model did not bring enough patient-
benefit. Baseline patient characteristics are presented in
Table 1. There were no statistical differences in patient
demographics between the intervention and control groups.
Health-Related QoL and Related End Points
Estimated mean QoL scores for both groups over time are
presented in Figure 2. The time × group interaction effect
was not found significant (P = .067), nor was the effect of
the type of treatment and age (all P. .05). Significant main
effects were found for prior systemic cancer drug treatment
(average FACT-G score of 76.19 v 72.60 in the benefit of
patients who received no prior systemic cancer drug;
P = .039), baseline scores on EQ-5D VAS (positive asso-
ciation of 0.28; P , .001), and baseline scores on CCS
(negative association of –0.65; P, .001). Post hoc pairwise
comparison of the time × group interaction effect dem-
onstrated equivalence of both groups. Similar to the primary
end point, the time × group interaction effect appeared to
be not significant for the secondary PROMs EQ-5D-3L (VAS
and GQ), DT, CCS, and HADS, following to the same
statistical model.
Service Use and Cost Data
For those patients receiving subcutaneous anticancer
drugs at home (full OHH), it was calculated that patients
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from the intervention group had on average 7.6 DCU visits
less than the control group during the first 12 weeks of
treatment (average of 5.6 6 3.0 and 13.2 6 4.6, re-
spectively, P = .011). Themedian number of hospitalization
days for the intervention group was 0 (interquartile
range = 0; range, 0-0) versus 3.5 (interquartile range = 12;
range, 0-12) for the control group.
For those patients being prepared at home for therapy
administration at the oncology DCU (partial OHH), the
average number of DCU visits did not differ from the control
group (6.86 2.5 and 7.56 3.1, respectively, P. .05). For
the intervention group, on average, 5.3 (62.6) home visits
were performed during study participation. For the group of
patients suitable for partial oncologic home-hospitalization,
there was no statistical difference in the number of hos-
pitalization days between both groups (average of
3.8 6 10.6 for the intervention group v 2.8 6 6.8 for the
control group, P . .05).
Service use and cost data gathered by patients during this
clinical trial turned out to be insufficiently consistent for a
thorough cost-comparison analysis.
Safety
No adverse events linked to the home-intervention were
recorded by the coordinating nurses during the course of
the study. The time × group interaction had no significant
effect on the patient’s reported feeling of safety on the VAS
(P = .984). Analysis of the study-specific and PREOS-PC
questionnaire demonstrated that of the intervention group,
48 patients reported to feel at home as safe as at the DCU,
seven felt more safe at home, whereas one reported to feel
more safe at the oncology DCU. Eight patients (two from the
intervention group and six from the control group) expe-
rienced a medical error during their general cancer treat-
ment, but none of these were related to the intervention
examined in this study.
Satisfaction and Preferences
There was no significant effect of the time × group inter-
action on the four domains of the OUT-PATSAT35 ques-
tionnaire. However, after 12 weeks of home-hospitalization,
43 out of 49 patients of the OHH group that completed the
study-specific satisfaction and preferences questionnaire
at study end declared to be highly satisfied with the new
care model. Three patients registered to be dissatisfied, but
they all preferred the intervention model to be continued for
the remaining of their therapy. Forty out of 52 patients of the
intervention group indicated the intervention had a positive
impact on their QoL. In total, 66 out of 110 (60%) patients
indicated they preferred OHH above SOC for the remaining
of treatment. Seventy-two of 106 (68%) patients declared
they would recommend the explored care model to fellow
patients (Fig 3).
After 12 weeks of study participation, 16 out of 52 patients
allocated to the control group and still in need of cancer
therapy chose to continue their treatment with OHH. Of
those, 13 of 15 responders declared after 8 weeks to be
(highly) satisfied and 11 of 14 responders acknowledged
the intervention had a positive impact on their QoL. Eleven
of 14 patients would recommend the interventions to fellow
patients.
Patients meeting inclusion criteria
(May 2018-January 2019; N = 251)
Patients were randomly assigned 
(n = 148)
Patients were allocated to     (n = 74) 
    home-hospitalization
Received full OHH                      (n = 5)a
Received partial OHH            (n = 69)b
Patients discontinued prematurely (n = 15)c
Treatment discontinuation or
    death
Discontinuation of OHH
Discontinuation of questionnaire
    completion




to standard of care (n = 74)
Patients declined study participation               (n = 103)
Reason
  No interest in study participation
  Overwhelming first cancer treatment
  Partial OHH impossible at day –1








    death
Discontinuation of questionnaire
    completion
(n = 7)
(n = 6)
Patients discontinued prematurely (n = 13)c
FIG 1. Patient inclusion flowchart. aSubcutaneous cancer drug administration at home; bpreparation for cancer therapy at home; Cdiscontinuation within first
12 weeks of study participation. OHH, oncologic home-hospitalization.
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TABLE 1. Patient Demographics
Characteristics Intervention Group Control Group Overall P
No. of patients 74 74 148 NA
Age, avg 6 SD 63.8 6 12.8 63.0 6 13.0 63.4 6 12.8 .698
Age category, years, No. (%)
≤ 65 36 (48.6) 39 (52.7) 75 (50.7) .742
. 65 38 (51.4) 35 (47.3) 73 (49.3)
Sex, No. (%)
Male 29 (39.2) 26 (35.1) 55 .734
Female 45 (60.8) 48 (64.9) 93
Cancer type, No. (%)
Breast 24 (32.4) 24 (32.4) 48 (32.4) .301
Digestive 15 (20.3) 17 (23.0) 32 (21.6)
Dermatology 2 (2.7) 1 (1.4) 3 (2.0)
Gynecologic 3 (4.1) 7 (9.5) 10 (6.8)
Head and neck 2 (2.7) 0 (0.0) 2 (1.4)
Hematologic 11 (14.9) 14 (19.0) 25 (16.9)
Lung 13 (17.6) 5 (6.8) 18 (12.2)
Urologic 4 (5.4) 6 (8.1) 10 (6.8)
Treatment intent, No. (%)
Curative 24 (32.4) 27 (36.5) 51 (34.5) .605
Palliative 39 (52.7) 33 (44.6) 72 (48.6)
Maintenance 11 (14.9) 14 (18.9) 25 (16.9)
Previous systemic cancer treatment, No. (%)
Yes 29 (39.2) 26 (35.1) 55 (37.2) .734
No 45 (60.8) 48 (64.9) 93 (62.8)
Type of therapy, No. (%)
SC drug eligible for OHH 5 (6.8) 6 (8.1) 11 (7.4) .952
SC or IV not eligible for OHH 68 (91.9) 67 (90.6) 135 (91.2)
Transfusion 1 (1.4) 1 (1.4) 2 (1.4)
Social status, No. (%)
Married or living together 55 (74.3) 51 (68.9) 106 (71.6) .580
Single 5 (6.8) 4 (5.4) 9 (6.1)
Divorced 3 (4.1) 4 (5.4) 7 (4.7)
Widowed 7 (9.5) 13 (16.2) 20 (13.5)
Missing 4 (5.4) 2 (2.7) 6 (4.1)
Education level, No. (%)
Elementary school 2 (2.7) 0 (0) 2 (2.7) .630
Lower high school (15 years) 21 (28.4) 22 (29.7) 43 (29.1)
Higher high school (18 years) 26 (35.1) 23 (31.1) 49 (33.1)
Bachelor degree 14 (18.9) 19 (25.7) 33 (22.3)
Master degree 5 (6.8) 6 (8.1) 11 (14.9)
Unknown 6 (8.1) 4 (5.4) 10 (6.8)
Hospital-distance, km, avg 6 SD 9.2 6 4.3 9.9 6 5.1 9.6 6 4.7 .349
Abbreviations: avg, average; NA, not applicable; OHH, oncologic home-hospitalization; SD, standard deviation.
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Model Efficiency
In light of this clinical trial, 399 home visits were conducted:
47 for the administration of a subcutaneous anticancer
products and 352 to prepare patients for cancer therapy
administration at the oncology DCU. In 12 cases of partial
OHH, next-day DCU visit was canceled based upon the
information gathered during the home visit. Full OHH
resulted in disappearance of waiting time before product
administration. The average waiting time was calculated at
2 hours and 20 minutes (SD = 1 hour 8 minutes) in the
control group. In case of partial OHH, the average waiting
time for therapy administration was reduced with 45%
compared with SOC (2 hours 36 minutes 6 1 hour 4





























Week 4 Week 8 Week 12
FIG 2. Estimated mean quality of life based on
FACT-G for both groups over time, adjusted for
baseline characteristics. FACT-G, Functional As-
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FIG 3. Patient-reported satisfaction and preferences for oncologic home-hospitalization compared with standard ambulatory care after 12 weeks of
study participation: (A) satisfaction with home-hospitalization, (B) impact of home-hospitalization on quality of life, (C) caremodel of preference after 12
weeks of study, and (D) recommendation of home-hospitalization to fellow sufferers.
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DISCUSSION
In this study, the quality of a model for OHH was compared
with SOC. From the inclusion number, we learned that
about 60% of the target population is in favor of our model
for OHH. The intervention had an equivalent effect on
patient-reported QoL and related end points as compared
to SOC. Nevertheless, large majority of patients allocated to
the intervention group reported to be highly satisfied with
the new caremodel and preferred it above SOC. In addition,
a large proportion of the intervention group declared that
the home-intervention had a positive impact on their QoL.
The contradictory results of the quantitative and qualitative
evaluations suggest that the effect of the intervention could
not be detected by the generic validated PROMs. New
outcome measures focusing on the burden of cancer
treatment instead of on the burden of the disease itself
should be developed.9
In terms of service use and efficiency, this trial showed that
for patients eligible for subcutaneous administration at
home, an average of 7.6 DCU visits were avoided within a
period of 3 months. Unfortunately, this subgroup was too
small to evaluate the potential effects on PROMs of this
obvious patient comfort. For those patients allocated to
partial OHH, the waiting times for therapy administration at
the oncology DCUwere reduced with an average of 45%. At
last, this trial demonstrated that such innovative care model
can be performed with the same level of safety as standard
ambulatory cancer care, which is similar to previous
observations.7
When applying these results to the quality principle of the
Institute of Medicine, we can conclude that evidence of
quality was provided for all domains, with the exception of
cost-efficiency. As result of the poor quality of patient-
reported cost data, a planned cost comparison from pa-
tients’ perspective could not be conducted. An evaluation
from perspective of the health care provider and/or payer
might be of greater value to evaluate the financial feasibility
of the model and should be subject of further research.
Another important limitation of this study is the proportional
difference of patients being allocated to partial versus full
OHH (92% v 8%, respectively). Albeit the small number of
patients included in the full OHH model, the authors are
truly convinced of the importance of evaluating this op-
portunity. The aim of this study was to explore the possi-
bilities of OHH and in this first evaluation, only azacitidine
and bortezomib were selected as suitable candidates for
home-administration. This selection was based on clinical
experience, their favorable toxicity profile, and their logis-
tical benefit. The positive results and experiences of this
trial allow further exploration of the full OHHmodel with new
candidates for home-administration. In addition, this trial
demonstrated that partial OHH can also have a large impact
on the patients’ experiences and DCU efficiency. This in-
termediate step might favor the perception toward home-
hospitalization of a lot of stakeholders and is believed to be
a crucial preparatory step toward further expansion of full
oncologic home-hospitalization. According to our knowl-
edge, this is the first documented study exploring the ef-
fects of partial oncologic home-hospitalization. Similar
initiatives focused on the day-1 principle to reduce patient
waiting times, but did not involve specialized home-
interventions.18,19 At last, this study was prone to selection
bias as result of the impossibility of blinding the interven-
tion. A cross-over design might partially address this issue,
albeit patients will always have preference for one of the two
care models.
The strengths of this randomized trial compared with
others available in the known literature are the large
sample size, the limited number of inclusion criteria
leading to a representative study-population, and the
evaluation of a large set of quality-indicators. In addition,
this was the first trial, to our knowledge, evaluating the
effects of partial OHH.
In conclusion, given the increasing number of patients with
cancer in need of systemic treatment and the evolution
toward safer treatment options, (partial) oncologic home-
hospitalization offers a high-quality and patient-centered
alternative to the current ambulatory cancer care for a large
proportion of patients with cancer. Authorities should en-
courage such initiatives and provide health care providers
with suitable legal and financial frameworks allowing
implementation of such innovative transmural care models
in daily practice. Nevertheless, further research is needed
to investigate the financial impact of such models.
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